Denise C Connolly

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Development of a syngeneic mouse model of epithelial ovarian cancer
    Bridget A Quinn
    Women s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    J Ovarian Res 3:24. 2010
  2. ncbi Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007
  3. ncbi Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
    Denise C Connolly
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:1389-97. 2003
  4. ncbi Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  5. ncbi Activation of cancer-specific gene expression by the survivin promoter
    Rudi Bao
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:522-8. 2002
  6. ncbi RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
  7. ncbi NEDD9 promotes oncogenic signaling in mammary tumor development
    Eugene Izumchenko
    Program in Molecular and Translational Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Res 69:7198-206. 2009
  8. ncbi Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53
    Bridget A Quinn
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    PLoS ONE 4:e8404. 2009

Collaborators

Detail Information

Publications8

  1. ncbi Development of a syngeneic mouse model of epithelial ovarian cancer
    Bridget A Quinn
    Women s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    J Ovarian Res 3:24. 2010
    ..The objective of this study was to establish an immunocompetent syngeneic mouse model of disseminated epithelial ovarian cancer (EOC) to facilitate laboratory-based studies of ovarian tumor biology and preclinical therapeutic strategies...
  2. ncbi Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007
    ..Our results demonstrate that MRI is well tolerated and can be repeated in serial imaging studies, permitting quantitative analysis of tumor growth and progression and response to therapeutic interventions...
  3. ncbi Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
    Denise C Connolly
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:1389-97. 2003
    ....
  4. ncbi Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  5. ncbi Activation of cancer-specific gene expression by the survivin promoter
    Rudi Bao
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:522-8. 2002
    ..Thus, the survivin promoter may be useful in controlling gene expression in cancer cells...
  6. ncbi RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
    ....
  7. ncbi NEDD9 promotes oncogenic signaling in mammary tumor development
    Eugene Izumchenko
    Program in Molecular and Translational Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Res 69:7198-206. 2009
    ..This study provides the first in vivo evidence of a role for NEDD9 in breast cancer progression and suggests that NEDD9 expression may provide a biomarker for tumor aggressiveness...
  8. ncbi Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53
    Bridget A Quinn
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    PLoS ONE 4:e8404. 2009
    ..In addition to mutation of BRCA1, mutation of the p53 gene is often found in patients with inherited breast and ovarian cancer syndrome...